Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease that accounts for 10–15% of adult and 25% of childhood ALL cases. Despite advances in therapy of T-ALL, relapsed disease remains a leading cause of death. The genetic and biological determinants of treatment failure and clinical outcomes remain incompletely understood.